إعلان
إعلان

ADIL

ADIL logo

Adial Pharmaceuticals, Inc

0.24
USD
برعاية
+0.01
+3.64%
٠٩ يناير, ١٥:٤١ UTC -5
مغلق
exchange

بعد الإغلاق

0.25

0.00
+1.65%

تقارير أرباح ADIL

النسبة الإيجابية المفاجئة

ADIL تفوق 13 من 25 آخر التقديرات.

52%

التقرير التالي

بيانات التقرير القادم
٠٢ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.08
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
--
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-77.14%

Adial Pharmaceuticals, Inc earnings per share and revenue

On ١٣ نوفمبر ٢٠٢٥, ADIL reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.14 USD, resulting in a 43.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 المحللين forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an زيادة of 0.00% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Adial Pharmaceuticals, Inc reported EPS of -$0.08, beating estimates by 43.98%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.91%, changed from $0.32 before the earnings release to $0.33 the day after.
The next earning report is scheduled for ٠٢ مارس ٢٠٢٦.
Based on 5 المحللين, Adial Pharmaceuticals, Inc is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان